Laura Fogliatto
Overview
Explore the profile of Laura Fogliatto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
255
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zinzani P, Wang H, Feng J, Kim T, Tao R, Zhang H, et al.
Blood Adv
. 2024 Jul;
8(18):4866-4876.
PMID: 39058951
Copanlisib, a pan-class I phosphatidylinositol 3-kinase inhibitor with predominant activity against the α and δ isoforms, previously demonstrated durable responses as monotherapy and improved progression-free survival (PFS) in combination with...
2.
Delamain M, Cardoso A, Pericole F, da Silva Araujo S, Fogliatto L, Higashi M, et al.
Oncol Ther
. 2024 Jun;
12(3):585-598.
PMID: 38829416
Introduction: RTXM83, a biosimilar of rituximab, was approved after physicochemical, functional, non-clinical, and clinical studies demonstrated their similarity; these studies included RTXM83-AC-01-11, a multicentric double-blind international prospective pivotal study. Long-term...
3.
Zinzani P, Thieblemont C, Melnichenko V, Bouabdallah K, Walewski J, Majlis A, et al.
Blood
. 2023 May;
142(2):141-145.
PMID: 37130017
Previous analyses of the phase 2 KEYNOTE-170 (NCT02576990) study demonstrated effective antitumor activity and acceptable safety of pembrolizumab 200 mg given every 3 weeks for up to 35 cycles (∼2...
4.
Niemann C, Awan F, Fogliatto L, Nikitin E, Samoilova O, Habib A, et al.
Hemasphere
. 2022 Sep;
6(10):e780.
PMID: 36168519
No abstract available.
5.
Pfister V, Marques F, Parra F, Yamamoto M, Vescovi Goncalves M, Perobelli L, et al.
EJHaem
. 2022 Sep;
3(3):698-706.
PMID: 36051063
Chronic lymphocytic leukaemia (CLL) has a highly variable clinical course. In addition to biological factors, socioeconomic factors and health system characteristics may influence CLL outcome. Data from the Brazilian Registry...
6.
Pavlovsky M, Cubero D, Agreda-Vasquez G, Enrico A, Mela-Osorio M, San Sebastian J, et al.
JCO Glob Oncol
. 2022 Apr;
8:e2100265.
PMID: 35486884
Purpose: Real-world evidence on non-Hodgkin lymphoma (NHL) management in Latin America is currently lacking. The objective of this study was to describe treatment characteristics and outcomes of NHL in Latin...
7.
Seguro F, Silva C, Moura C, Conchon M, Fogliatto L, Funke V, et al.
Hematol Transfus Cell Ther
. 2020 Jul;
43(2):191-200.
PMID: 32631809
This manuscript summarizes the results of the consensus meeting composed of hematologists and cardiologists to establish recommendations for the prevention and follow-up of cardiovascular (CV) risk in patients with chronic...
8.
Armand P, Rodig S, Melnichenko V, Thieblemont C, Bouabdallah K, Tumyan G, et al.
J Clin Oncol
. 2019 Oct;
37(34):3291-3299.
PMID: 31609651
Purpose: Patients with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) have a poor prognosis, and their treatment represents an urgent and unmet need. Because PMBCL is associated with...
9.
Candelaria M, Gonzalez D, Delamain M, Bar D, Beniwal S, Dasappa L, et al.
Leuk Lymphoma
. 2019 Jul;
60(14):3375-3385.
PMID: 31272251
This multicenter, double-blind, randomized study compared the efficacy, pharmacokinetics (PKs)/pharmacodynamics (PDs), safety and immunogenicity profile of RTXM83 vs. reference rituximab (R-rituximab), both with CHOP, as first-line treatment of diffuse large...
10.
Fogliatto L, Grokoski K, Strey Y, Vanelli T, Fraga C, Barra M, et al.
Hematol Transfus Cell Ther
. 2019 Feb;
41(1):50-56.
PMID: 30793105
Background: Diffuse large B-cell lymphoma, among non-Hodgkin lymphomas, is one of the most frequent subtypes. Clinical laboratory data and post-treatment outcomes are scarce in the Brazilian population. Objective: The main...